Atea Pharmaceuticals(AVIR)

Focus: Atea Pharmaceuticals is a public biotech company focused on nucleoside and nucleotide analogs targeting viral RNA polymerase, with a pipeline concentrated in hepatitis C and dengue antivirals.

Neurology Gene Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Atea Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Atea Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AT-527

Hepatitis C

Phase 2

Clinical Trials (5)

NCT04019717Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Phase 2

Help build intelligence for Atea Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline concentrated on Phase 3 hepatitis C programs (bemnifosbuvir and ruzasvir) with 15 active trials providing near-term catalysts
Specialized focus on viral polymerase inhibitors creates deep technical expertise opportunity in an underexplored modality
Publicly traded with access to capital markets, offering equity upside potential if pipeline programs advance

Watch Out For

Significant cash burn with $168M net loss in FY2025 against only $65M cash position, creating 3-4 month runway pressure
Zero currently open job requisitions indicates potential hiring freeze or constrained growth phase
No approved products or revenue generation means no commercial stability or established market position

Generated by Claude from Atea Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT04396106Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

Phase 2

NCT04309734Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Phase 1/2

AT-752

Dengue

Phase 2

Clinical Trials (3)

NCT05466240Study of AT-752 in Patients With Dengue Infection

Phase 2

NCT04722627Study of AT-752 in Healthy Subjects

Phase 1

NCT05366439Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Phase 1

bemnifosbuvir

Hepatitis C

Phase 3

Clinical Trials (5)

NCT07037277C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Phase 3

NCT06868264C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Phase 3

NCT05629962SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Phase 3

+2 more

ruzasvir

Hepatitis C

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 24 clinical trials

Top TAs: Infectious Diseases, Gastroenterology, Nephrology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

11 pipeline

3 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$144M26%

Net Income

-$168M

Cash

$65M

Source: SEC 10-K Filing

Risk Signals

WARN Act Layoff Notices (1)

2024-10-15

— Boston, MA

source

Source: state DOL filings, aggregated via Big Local News

No recent public compliance or operational warnings detected, but extreme cash burn and zero hiring indicate restructuring risk if Phase 3 data disappoints.